Xeris Biopharma Holdings Inc (XERS)
2.26
+0.06
(+2.73%)
USD |
NASDAQ |
Jun 27, 16:00
2.25
-0.01
(-0.44%)
After-Hours: 20:00
Xeris Biopharma Holdings Net Income (Annual): -62.26M for Dec. 31, 2023
Net Income (Annual) Chart
Historical Net Income (Annual) Data
Date | Value |
---|---|
December 31, 2023 | -62.26M |
December 31, 2022 | -94.66M |
December 31, 2021 | -122.72M |
December 31, 2020 | -91.14M |
Date | Value |
---|---|
December 31, 2019 | -125.58M |
December 31, 2018 | -60.08M |
December 31, 2017 | -26.55M |
December 31, 2016 | -13.21M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Annual) Range, Past 5 Years
-125.58M
Minimum
2019
-62.26M
Maximum
2023
-99.27M
Average
-94.66M
Median
2022
Net Income (Annual) Benchmarks
Amgen Inc | 6.717B |
Regeneron Pharmaceuticals Inc | 3.954B |
Kodiak Sciences Inc | -260.49M |
INmune Bio Inc | -30.01M |
Phathom Pharmaceuticals Inc | -201.59M |